Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 11:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 1,657 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Renal Insufficiency,Chronic Clear all
Active, not recruiting No phase listed Observational

Acute Kidney Injury Genomics and Biomarkers in TAVR Study

NCT02791880
View directory record Official record
Conditions
Acute Kidney Injury, Renal Insufficiency, Chronic, Heart Failure, Myocardial Infarction, Arrhythmias, Cardiac, Stroke
Interventions
Transcatheter Aortic Valve Replacement
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2031
U.S. locations
3
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 11, 2026, 11:32 AM EDT
Completed Phase 1 Interventional

CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)

NCT04990427
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
CLBS201
Drug
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 11, 2026, 11:32 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Applications of MRI in Kidney Disease

NCT02832505
View directory record Official record
Conditions
Chronic Kidney Disease, End-stage Kidney Disease
Interventions
No intervention but only observational
Other
Lead sponsor
University of Minnesota
Other
Eligibility
45 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 11, 2026, 11:32 AM EDT
Terminated Phase 2 Interventional Results available

Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI

NCT03602261
View directory record Official record
Conditions
Secondary Hyperparathyroidism Due to Renal Causes, Chronic Kidney Diseases, Vitamin D Deficiency, Stage 5 Chronic Kidney Disease
Interventions
Calcifediol Oral Capsule, Placebo oral capsule
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
18
States / cities
Peoria, Arizona • Phoenix, Arizona • Cypress, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 11, 2026, 11:32 AM EDT
Recruiting Not applicable Interventional

Incremental Hemodialysis: The TwoPlus Trial

NCT05828823
View directory record Official record
Conditions
End-Stage Kidney Disease
Interventions
Hemodialysis twice weekly, Hemodialysis thrice weekly
Device · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
10
States / cities
Jacksonville, Florida • Atlanta, Georgia • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 11, 2026, 11:32 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease

NCT07235059
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
OJR520, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 11, 2026, 11:32 AM EDT
Recruiting Not applicable Interventional

Transcutaneous Auricular Vagus Nerve Stimulation Device in CKD Population

NCT05981183
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Transcutaneous electrical nerve stimulation unit (TENS)
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 11, 2026, 11:32 AM EDT
Completed Not applicable Interventional

24 Hour Use of the Wearable Artificial Kidney

NCT02280005
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
WAK Treatment
Device
Lead sponsor
Blood Purification Technologies, Inc.
Industry
Eligibility
21 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Oct 11, 2026, 11:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021)

NCT04994522
View directory record Official record
Conditions
End Stage Renal Disease, Renal Impairment
Interventions
Belzutifan
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 11, 2026, 11:32 AM EDT
Terminated Phase 1 Interventional Results available

Single Dose Pravastatin Pharmacokinetics in Pediatric Peritoneal Dialysis Patients

NCT00571194
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
pravastatin
Drug
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
12 Months to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 11, 2026, 11:32 AM EDT
Completed Phase 3 Interventional

Telemonitoring to Improve Outcomes of Patients With Chronic Kidney Disease (CKD)

NCT01446029
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Video Telemonitoring Device with Clinical Care Modules
Device
Lead sponsor
Minneapolis Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 85 Years
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 4, 2014 · Synced Oct 11, 2026, 11:32 AM EDT
Completed Phase 1 Interventional

Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With End-Stage Renal Disease

NCT01840956
View directory record Official record
Conditions
End-stage Renal Disease, Kidney Failure, Chronic
Interventions
HAVG
Biological
Lead sponsor
Humacyte, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Durham, North Carolina • Houston, Texas • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 19, 2022 · Synced Oct 11, 2026, 11:32 AM EDT
Completed Phase 4 Interventional

Pharmacokinetics of Immunosuppressants in Renal Transplant Candidates Who Have Undergone Laparoscopic Sleeve Gastrectomy

NCT02221583
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Astagraf XL, Prograf, Mycophenolate mofetil
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
19 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 11, 2026, 11:32 AM EDT
Completed Phase 4 Interventional

Pilot Study Evaluating Doxercalciferol Replacement Therapy in Kidney Transplant Recipients

NCT00889629
View directory record Official record
Conditions
Chronic Kidney Disease, Kidney Transplantation
Interventions
Doxercalciferol, placebo, 25-OH Vitamin D3
Drug
Lead sponsor
Mariana Markell
Other
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2019 · Synced Oct 11, 2026, 11:32 AM EDT
Enrolling by invitation Phase 2 Interventional

Senescence in Chronic Kidney Disease

NCT02848131
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Group 2: Dasatinib, Group 2: Quercetin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 11, 2026, 11:32 AM EDT
Terminated Phase 1 Interventional

Efficacy, Safety Study and Benefit of Alkali Therapy in Sickle Cell Disease

NCT01894594
View directory record Official record
Conditions
Sickle Cell Anemia, Chronic Kidney Disease, Metabolic Acidosis
Interventions
Sodium Bicarbonate
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 11, 2026, 11:32 AM EDT
Completed Phase 1 Interventional Results available

Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab

NCT02275156
View directory record Official record
Conditions
Hyperlipidemia, Mixed Dyslipidemia
Interventions
Evolocumab
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Oct 11, 2026, 11:32 AM EDT
Completed Phase 2 Interventional Results available

Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)

NCT05027074
View directory record Official record
Conditions
End-Stage Renal Disease, End-Stage Kidney Disease, Kidney Failure, Chronic
Interventions
MK-2060, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
77
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 11, 2026, 11:32 AM EDT
Completed Phase 4 Interventional Results available

ISCHEMIA-Chronic Kidney Disease Trial

NCT01985360
View directory record Official record
Conditions
Cardiovascular Diseases, Coronary Artery Disease, Heart Diseases, Myocardial Ischemia, Kidney Disease, End Stage Renal Failure on Dialysis
Interventions
Cardiac Catheterization, Coronary Artery Bypass Graft Surgery, Percutaneous Coronary Intervention, Lifestyle, Medication
Procedure · Behavioral · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Enrollment
777 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Oct 11, 2026, 11:32 AM EDT
Terminated Phase 3 Interventional

ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

NCT05746559
View directory record Official record
Conditions
Chronic Kidney Disease, CKD, Cardiac Disease, Cardiopulmonary Bypass
Interventions
Placebo, Ravulizumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
16
States / cities
Orange, California • San Francisco, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 11, 2026, 11:32 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Chronic Kidney Disease in Relation to Alterations in Protein and Amino Acid Metabolism and Function

NCT01890811
View directory record Official record
Conditions
Chronic Kidney Failure
Interventions
Boost High Protein
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
55 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Oct 11, 2026, 11:32 AM EDT
Not listed Phase 2Phase 3 Interventional

Frequent Hemodialysis Network: Nocturnal Trial

NCT00271999
View directory record Official record
Conditions
End Stage Renal Disease, Hemodialysis
Interventions
Nocturnal home hemodialysis
Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 3, 2010 · Synced Oct 11, 2026, 11:32 AM EDT
Completed Not applicable Interventional

Using Shared Decision Making to Improve Kidney Transplantation Rates

NCT06141499
View directory record Official record
Conditions
End Stage Renal Disease, Kidney Failure
Interventions
Provider educational materials, Patient letters
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 11, 2026, 11:32 AM EDT
Withdrawn Phase 4 Interventional

Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure

NCT06995144
View directory record Official record
Conditions
Heart Failure, Edema, Pulmonary Congestion, Fluid Overload
Interventions
Extended Release Torsemide Tablets, Immedate Release Torsemide Tablets
Drug
Lead sponsor
Sarfez Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 11, 2026, 11:32 AM EDT